Bioventus (BVS) Other Non-Current Assets (2021 - 2022)
Bioventus (BVS) posted Other Non-Current Assets of $2.8 million for Q4 2022, down 94.45% on a QoQ basis from $50.0 million in Q2 2022, and down 94.45% year-over-year from $50.0 million in Q4 2021.
Bioventus (BVS) Other Non-Current Assets (2021 - 2022) Analysis & Trends
Bioventus' Other Non-Current Assets history runs 2 years deep, the most recent figure standing at $2.8 million for Q4 2022.
- Quarterly Other Non-Current Assets fell 94.45% year-over-year to $2.8 million in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $2.8 million (down 94.45% YoY) and the FY2022 annual result came in at $2.8 million, down 94.45% from the prior year.
- Other Non-Current Assets was $2.8 million for Q4 2022 at Bioventus, down from $50.0 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $50.0 million in Q4 2021 and bottomed at $2.8 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.88 Bn | 176.59 Bn | 6.27 Bn | - |
| 2 | Stryker | 128.95 Bn | 126.07 Bn | 3.81 Bn | 3.17 Bn |
| 3 | Medtronic | 108.68 Bn | 99.46 Bn | 6.41 Bn | 4.15 Bn |
| 4 | Boston Scientific | 68.54 Bn | 67.09 Bn | 3.61 Bn | 2.05 Bn |
| 5 | Edwards Lifesciences | 48.26 Bn | 44.58 Bn | 1.29 Bn | 738.90 Mn |
| 6 | Dexcom | 28.39 Bn | 27.28 Bn | 750.30 Mn | 285.90 Mn |
| 7 | GE HealthCare Technologies | 28.22 Bn | 25.93 Bn | 1.98 Bn | 2.25 Bn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | 164.00 Mn |
| 9 | Koninklijke Philips | 24.66 Bn | 21.54 Bn | 2.07 Bn | 828.89 Mn |
| 10 | Bioventus | 826.57 Mn | 790.72 Mn | 90.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 2.78 Mn |
| Apr 2, 2022 | 50.00 Mn |
| Dec 31, 2021 | 50.00 Mn |
| Oct 2, 2021 | 50.00 Mn |